NUVL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nuvalent, Inc. (NUVL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong pipeline, FDA breakthrough therapy designations, and upcoming potential FDA approvals make it a compelling growth opportunity in the oncology sector. Despite the lack of immediate trading signals and current financial losses, the positive momentum in analyst ratings, news catalysts, and technical indicators support a buy decision.
The technical indicators show a bullish trend with the MACD histogram above 0 and positively contracting, RSI at 63.62 in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 108.825), suggesting potential for further upside.
FDA breakthrough therapy designations for both neladalkib and zidesamtinib.
Upcoming pivotal data presentation at the 2026 ASCO Annual Meeting.
FDA acceptance of the NDA for zidesamtinib with a target action date of September 18,
Strong analyst sentiment with multiple buy ratings and increased price targets.
Financial losses with no revenue generation yet.
Stock trend analysis indicates potential short-term downside (-5.25% in the next week, -11.81% in the next month).
In Q4 2025, Nuvalent reported a net income loss of -$118.7M, which improved by 58.78% YoY. EPS also improved to -1.58, up 50.48% YoY. However, the company has yet to generate revenue, as it is still in the pre-commercialization phase.
Analysts are highly optimistic about Nuvalent. Wells Fargo initiated coverage with an Overweight rating and a $116 price target, citing 'best-in-class' potential for zidesamtinib. UBS raised its price target to $138, and Cantor Fitzgerald increased its target to $140, emphasizing the company's transition to a revenue story with upcoming product launches.
